receptor binding domain rbd  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc receptor binding domain rbd
    Study approach and distinct antibody responses to SARS-CoV-2 along with neutralization assay. (A) Outline delineating the experimental workflow. (B) Box plots showing the anti-SARS-CoV-2 <t>total,</t> <t>IgA,</t> IgM, and IgG antibody proportions in serum samples from controls, symptomatic- and asymptomatic-infected individuals and in contacts (C) . Pie chart showing the overall immunoglobulin response across subject groups. (D) Box plot depicting the percent inhibition of neutralizing antibodies in an in vitro spike <t>RBD-ACE2</t> interaction-based surrogate virus neutralization assay. Statistical comparisons were performed using unpaired Wilcoxon test. p-values are written against respective comparisons, where n = number of individuals; IgA, immunoglobulin A; IgM, immunoglobulin M; IgG, immunoglobulin G; control (n = 14), infected (n = 23), symptomatic (n = 10), asymptomatic (n = 13), and contact (n = 24).
    Receptor Binding Domain Rbd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/receptor binding domain rbd/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    receptor binding domain rbd - by Bioz Stars, 2023-03
    93/100 stars

    Images

    1) Product Images from "Single-Cell Immunogenomic Approach Identified SARS-CoV-2 Protective Immune Signatures in Asymptomatic Direct Contacts of COVID-19 Cases"

    Article Title: Single-Cell Immunogenomic Approach Identified SARS-CoV-2 Protective Immune Signatures in Asymptomatic Direct Contacts of COVID-19 Cases

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2021.733539

    Study approach and distinct antibody responses to SARS-CoV-2 along with neutralization assay. (A) Outline delineating the experimental workflow. (B) Box plots showing the anti-SARS-CoV-2 total, IgA, IgM, and IgG antibody proportions in serum samples from controls, symptomatic- and asymptomatic-infected individuals and in contacts (C) . Pie chart showing the overall immunoglobulin response across subject groups. (D) Box plot depicting the percent inhibition of neutralizing antibodies in an in vitro spike RBD-ACE2 interaction-based surrogate virus neutralization assay. Statistical comparisons were performed using unpaired Wilcoxon test. p-values are written against respective comparisons, where n = number of individuals; IgA, immunoglobulin A; IgM, immunoglobulin M; IgG, immunoglobulin G; control (n = 14), infected (n = 23), symptomatic (n = 10), asymptomatic (n = 13), and contact (n = 24).
    Figure Legend Snippet: Study approach and distinct antibody responses to SARS-CoV-2 along with neutralization assay. (A) Outline delineating the experimental workflow. (B) Box plots showing the anti-SARS-CoV-2 total, IgA, IgM, and IgG antibody proportions in serum samples from controls, symptomatic- and asymptomatic-infected individuals and in contacts (C) . Pie chart showing the overall immunoglobulin response across subject groups. (D) Box plot depicting the percent inhibition of neutralizing antibodies in an in vitro spike RBD-ACE2 interaction-based surrogate virus neutralization assay. Statistical comparisons were performed using unpaired Wilcoxon test. p-values are written against respective comparisons, where n = number of individuals; IgA, immunoglobulin A; IgM, immunoglobulin M; IgG, immunoglobulin G; control (n = 14), infected (n = 23), symptomatic (n = 10), asymptomatic (n = 13), and contact (n = 24).

    Techniques Used: Neutralization, Infection, Inhibition, In Vitro

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • receptor binding domain rbd  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc receptor binding domain rbd
    Study approach and distinct antibody responses to SARS-CoV-2 along with neutralization assay. (A) Outline delineating the experimental workflow. (B) Box plots showing the anti-SARS-CoV-2 <t>total,</t> <t>IgA,</t> IgM, and IgG antibody proportions in serum samples from controls, symptomatic- and asymptomatic-infected individuals and in contacts (C) . Pie chart showing the overall immunoglobulin response across subject groups. (D) Box plot depicting the percent inhibition of neutralizing antibodies in an in vitro spike <t>RBD-ACE2</t> interaction-based surrogate virus neutralization assay. Statistical comparisons were performed using unpaired Wilcoxon test. p-values are written against respective comparisons, where n = number of individuals; IgA, immunoglobulin A; IgM, immunoglobulin M; IgG, immunoglobulin G; control (n = 14), infected (n = 23), symptomatic (n = 10), asymptomatic (n = 13), and contact (n = 24).
    Receptor Binding Domain Rbd, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/receptor binding domain rbd/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    receptor binding domain rbd - by Bioz Stars, 2023-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Study approach and distinct antibody responses to SARS-CoV-2 along with neutralization assay. (A) Outline delineating the experimental workflow. (B) Box plots showing the anti-SARS-CoV-2 total, IgA, IgM, and IgG antibody proportions in serum samples from controls, symptomatic- and asymptomatic-infected individuals and in contacts (C) . Pie chart showing the overall immunoglobulin response across subject groups. (D) Box plot depicting the percent inhibition of neutralizing antibodies in an in vitro spike RBD-ACE2 interaction-based surrogate virus neutralization assay. Statistical comparisons were performed using unpaired Wilcoxon test. p-values are written against respective comparisons, where n = number of individuals; IgA, immunoglobulin A; IgM, immunoglobulin M; IgG, immunoglobulin G; control (n = 14), infected (n = 23), symptomatic (n = 10), asymptomatic (n = 13), and contact (n = 24).

    Journal: Frontiers in Immunology

    Article Title: Single-Cell Immunogenomic Approach Identified SARS-CoV-2 Protective Immune Signatures in Asymptomatic Direct Contacts of COVID-19 Cases

    doi: 10.3389/fimmu.2021.733539

    Figure Lengend Snippet: Study approach and distinct antibody responses to SARS-CoV-2 along with neutralization assay. (A) Outline delineating the experimental workflow. (B) Box plots showing the anti-SARS-CoV-2 total, IgA, IgM, and IgG antibody proportions in serum samples from controls, symptomatic- and asymptomatic-infected individuals and in contacts (C) . Pie chart showing the overall immunoglobulin response across subject groups. (D) Box plot depicting the percent inhibition of neutralizing antibodies in an in vitro spike RBD-ACE2 interaction-based surrogate virus neutralization assay. Statistical comparisons were performed using unpaired Wilcoxon test. p-values are written against respective comparisons, where n = number of individuals; IgA, immunoglobulin A; IgM, immunoglobulin M; IgG, immunoglobulin G; control (n = 14), infected (n = 23), symptomatic (n = 10), asymptomatic (n = 13), and contact (n = 24).

    Article Snippet: For IgA and IgM quantification, receptor binding domain (RBD) (SARS-CoV-2 spike RBD recombinant protein, mFc-Tag, CST # 41701S) antigen at a concentration of 200 ng/well was coated in a 96-well high binding microtiter plate (HIMEDIA-EP1) in 1× Tris-buffered saline (TBS) pH-7.4 for 2 h at 37°C.

    Techniques: Neutralization, Infection, Inhibition, In Vitro